Mol-CycleGAN – a generative model for molecular optimization

Topic:

Designing a molecule with desired properties is one of the biggest challenges in drug development, as it requires optimization of chemical compound structures with respect to many complex properties. To augment the compound design process we introduce Mol-CycleGAN – a CycleGAN-based model that generates optimized compounds with high structural similarity to the original ones. Namely, given a molecule our model generates a structurally similar one with an optimized value of the considered property. We evaluate the performance of the model on selected optimization objectives related to structural properties (presence of halogen groups, number of aromatic rings) and to a physicochemical property (penalized logP). In the task of optimization of penalized logP of drug-like molecules our model significantly outperforms previous results.

Read more

https://arxiv.org/pdf/1902.02119.pdf

You might be also interested in:

Poster: Bridging the Phenotype-Proteome Gap: A Multi-Modal AI Framework for analysis of Cell Painting images
Biomedical knowledge graph connecting drug discovery data, disease biology, targets and indications to support target prioritization and indication expansion
Knowledge Graphs in Drug Discovery: Bringing Context to Internal Data Assets
Molecular structure representing AI-supported antibody design for blood-brain barrier research
How BBB-Penetrating Antibodies Cross the Blood-Brain Barrier
Life sciences conference takeaways 2026 - AACR, PEGS Boston, SLAS Europe, and Bio-IT World summary on AI in drug discovery
What 4 Life Sciences Conferences Revealed About AI in Drug Discovery

Contact

Ready to transform drug discovery?

Discover how one of the top AI CROs in the world, can be your trusted partner in revolutionizing drug discovery through AI.

Contact us today to learn more about our tailored solutions for empowering your drug development journey.

Send us a message and we will contact you back within 48 hours.

Newsletter

Become an insider

Be the first to know about Ardigen’s latest news and get access to our publications, webinars and more!